Select Page

Cook Biotech acquires assets of AcuityBio, expanding its technology portfolio

West Lafayette, Indiana – Cook Biotech Inc., a leader in advanced biomaterials and regenerative medicine, announced today that it has expanded its technology portfolio by acquiring the assets of AcuityBio Inc., a developer of novel drug-delivery combination products.

AcuityBio founding CEO, John “Jay” Schwartz, PhD, said, “Our goal from the very beginning was to develop new and more effective treatment options for patients with lung and other cancers. This acquisition accelerates the path to market for the technologies researched and developed by AcuityBio over the last 12 years and advances both companies’ corporate missions of providing novel therapies that improve patients’ lives.”

The companies formed an initial relationship in 2018 to leverage AcuityBio’s drug-delivery expertise with Cook Biotech’s unique medical device technology. The results of the partnership sped development of AcuityBio’s lead drug-eluting staple line buttress combination product, ABC103 for lung cancer, and resulted in the acquisition by Cook.

Cook Biotech President Umesh Patel, PhD, said, “This acquisition was the next logical step in our relationship. Our team is very motivated to complete the work to get this combination product in clinicians’ hands to help lung cancer patients.”

Dr. Patel also said, “For more than 25 years, our extracellular matrix (ECM) technology has been used to improve the lives of patients worldwide. Now with AcuityBio’s drug-delivery platform on board, we hope to develop other combination products to locally deliver a diverse set of therapeutic compounds providing solutions for critical unmet medical needs and potentially saving patient lives.”

The terms of the agreement remain confidential.

About Cook Biotech

Cook Biotech Inc. develops and manufactures medical products for tissue repair and regenerative medicine applications using proprietary extracellular matrix (ECM) technologies and processes. Cook Biotech products are marketed and distributed under several brand names, including Biodesign® and OASIS®. Cook Biotech collaborates with partners and distributors, including AxoGen Inc., Aziyo Biologics, Cook Medical Inc., Cormatrix, Katena Products Inc., Keystone Dental Inc., and Smith & Nephew Inc., to develop new products and provide technical support. Cook Biotech was established in 1995 and is affiliated with Cook Medical Holdings in Bloomington, Indiana. It is located in the Purdue Research Park in West Lafayette, Indiana. For more information, visit www.cookbiotech.com.